Academic Journal
Two-year abatacept retention rate in clinical practice in the French ACTION cohort
| Title: | Two-year abatacept retention rate in clinical practice in the French ACTION cohort |
|---|---|
| Authors: | Mariette, Xavier, Schaeverbeke, Thierry, Gaudin, Philippe, Chartier, Mélanie, Heitzmann, Julia, Vannier-Moreau, Virginie, Hilliquin, Pascal, Cantagrel, Alain |
| Contributors: | Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)-Groupe hospitalier Pellegrin, Groupe de Recherche et d'Etude du Processus Inflammatoire (GREPI), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes 2016-2019 (UGA 2016-2019 ), Centre Hospitalier Universitaire CHU Grenoble (CHUGA), Bristol-Myers Squibb Company, Excelya, Centre Hospitalier Sud Francilien, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Source: | Joint Bone Spine. 86:753-759 |
| Publisher Information: | Elsevier BV, 2019. |
| Publication Year: | 2019 |
| Subject Terms: | Adult, Male, MESH: Rheumatoid Factor, Internationality, Biologic, Rheumatoid / diagnosis, [SDV]Life Sciences [q-bio], National specificity, MESH: Dose-Response Relationship, MESH: Arthritis, MESH: Drug Administration Schedule, MESH: Medication Adherence / statistics & numerical data, Severity of Illness Index, Drug Administration Schedule, MESH: Body Mass Index, Body Mass Index, Abatacept, Arthritis, Rheumatoid, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Rheumatoid Factor, MESH: Abatacept / administration & dosage, Humans, Prospective Studies, Rheumatoid arthritis, MESH: Cohort Studies, MESH: Treatment Outcome, Aged, 2. Zero hunger, MESH: Humans, Dose-Response Relationship, Drug, MESH: Antirheumatic Agents / administration & dosage, MESH: Follow-Up Studies, Middle Aged, Drug retention rate, Rheumatoid / drug therapy, MESH: Prospective Studies, Real-life study, Antirheumatic Agents, Patient Compliance, Female, France, Drug, MESH: Patient Compliance / statistics & numerical data, Follow-Up Studies |
| Description: | Abatacept retention rates were evaluated in the French cohort in the prospective ACTION study (2010-2013), which included patients with moderate-to-severe rheumatoid arthritis managed in everyday clinical practice and started on intravenous abatacept therapy.Two-year abatacept retention rates were evaluated in 455 patients classified according to treatment line, body mass index (BMI), and status for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).After 2 years, the overall abatacept retention rate was 44%. The retention rate was non-significantly higher in the patients with vs. without a history of unresponsiveness to at least one biologic (48.1% vs. 41.8%, respectively). No significant retention rate differences were found across BMI categories (444 patients |
| Document Type: | Article |
| Language: | English |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2019.07.006 |
| Access URL: | https://hal.archives-ouvertes.fr/hal-03489017/file/S1297319X19301125.pdf https://pubmed.ncbi.nlm.nih.gov/31352138 https://europepmc.org/abstract/MED/31352138 https://pubmed.ncbi.nlm.nih.gov/31352138/ https://www.sciencedirect.com/science/article/pii/S1297319X19301125 https://www.ncbi.nlm.nih.gov/pubmed/31352138 |
| Rights: | Elsevier TDM CC BY NC |
| Accession Number: | edsair.doi.dedup.....4c693b40e60d1fc822e92e7388ba2d7c |
| Database: | OpenAIRE |
| ISSN: | 1297319X |
|---|---|
| DOI: | 10.1016/j.jbspin.2019.07.006 |